Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label, Single/Multiple-dose Escalation, and Cohort Expansion Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Oral CSCJC3456 Tablets in Patients With Advanced Malignant Solid Tumors

NCT06717750 is registered in ClinicalTrials.gov with Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. as lead sponsor.

NCT NCT06717750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06717750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label, Single/Multiple-dose Escalation, and Cohort Expansion Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Oral CSCJC3456 Tablets in Patients With Advanced Malignant Solid Tumors
Lead sponsor
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
February 13, 2025
Completion date
June 30, 2028
Enrollment
102 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumors